PROTEOMICS INTERNATIONAL LABORATORIES LTD

GENETIC SIGNATURES LIMITEDGSS · Pharmaceuticals, Biotechnology & Life SciencesNewtown, Australia

65% matchPublic

Genetic Signatures Limited operates as a molecular diagnostics (MDx) enterprise, extending its reach across Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. The company engineers and manufactures an array of real-time Polymerase Chain Reaction (PCR)-based products, sold under the EasyScreen brand, for the identification of infectious diseases. Moreover, it offers its proprietary MDx 3Base platform technology, enabling hospitals and pathology laboratories to conduct comprehensive screenings for diverse infectious pathogens. Its offerings also encompass detection kits tailored for conditions such as gastrointestinal ailments, respiratory illnesses, sexual health concerns, antimicrobial resistance, meningitis, and tropical diseases. Founded in 2001, the firm is headquartered in Newtown, Australia.

BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for potential use in breast cancer prevention strategies, early screening, and ongoing patient monitoring. This in vitro diagnostic (IVD) technology functions by detecting a unique pattern of lipid biomarkers, which are isolated from extracellular vesicles present in a patient's plasma or blood, thereby enabling the diagnosis of breast cancer cells. Established in 2010, the company's main operations are based in Sydney, Australia.

GENETIC TECHNOLOGIES LIMITEDGTG · Pharmaceuticals, Biotechnology & Life SciencesFitzroy, Australia

65% matchPublic

Genetic Technologies Limited (GTG.AX), an Australian molecular diagnostics company founded in Fitzroy in 1987, delivers predictive genetic testing and risk assessment tools. These solutions empower medical professionals in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific to proactively manage patient health. The company operates through two distinct divisions: EasyDNA and GeneType/Corporate. Among its offerings is BREVAGenplus, a clinically validated test specifically designed for assessing the risk of non-hereditary breast cancer. This product is actively promoted to healthcare providers such as obstetricians/gynecologists, breast surgeons, and specialists in breast health and imaging centers. GTG.AX also provides an array of cancer risk assessment tests, notably GeneType for Colorectal Cancer and GeneType for Breast Cancer, and is currently developing new risk assessments for conditions including ovarian cancer, prostate cancer, coronary artery disease, and type 2 diabetes. In addition to its diagnostic services, the company offers broader genetic testing solutions spanning medical, animal, forensic, and plant applications. Genetic Technologies Limited has established research and collaboration agreements with several prominent institutions, including the University of Melbourne, Translational Genomics Research Institute, and Memorial Sloan Kettering New York Cambridge University.

PACIFIC EDGE LIMITEDPEB · Pharmaceuticals, Biotechnology & Life SciencesDunedin, New Zealand

63% matchPublic

Pacific Edge Ltd is a biotechnology research company headquartered in Dunedin, New Zealand, specializing in genomic diagnostics and the commercialization of the Cxbladder family of tests.

Beroni Group Limited, established in 2014 and based in Sydney, Australia, is a global enterprise operating in China, Australia, the United States, and Japan. The company specializes in the creation and distribution of a diverse portfolio of health and wellness products. Its offerings span several key areas: Smoking Harm Reduction: This includes products like NicoBloc, designed to aid in smoking cessation. Environmental Quality: Beroni provides air purification systems, such as Fogibloc, and water filtration solutions under the Olansi brand. Health and Wellness: The company supplies a variety of health supplements and also markets cosmetic products, including V show rejuvenation liquids and various hyaluronic acid and avocado-based intensive treatment masks. Stem cell-derived cosmetic products are also part of its range. Diagnostic Tools: Beroni is active in the diagnostics field, offering detection kits for viruses like the SARS-CoV-2 IgG/IgM antibody kit for COVID-19, as well as the CII-ArboViroPlex rRT-PCR assay, which identifies arboviruses such as Zika, Dengue, Chikungunya, and West Nile. Beyond product sales, Beroni Group is heavily invested in research and development. Its R&D efforts focus on discovering and developing novel pharmaceutical drugs, conducting clinical trials, and advancing anti-cancer therapies. The company also provides services in gene detection and diagnosis, infectious disease diagnostics, and offers cell therapies for both cancer treatment and anti-aging applications. Furthermore, Beroni manages an e-commerce platform dedicated to pharmaceutical and healthcare products.

OXFORD BIODYNAMICS PLCOBD · BiotechOxford, United Kingdom

67% matchPublic

Oxford BioDynamics Plc operates as a biotechnology firm that specializes in identifying and advancing biomarkers, primarily for the pharmaceutical and biotechnology sectors across global markets, including the United States. Its flagship offering is EpiSwitch, an exclusive technological platform employed for discovering, assessing, validating, and tracking epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These are crucial for developing medical diagnostic kits, predicting disease onset, aiding in diagnosis, and informing therapeutic strategies. The company's key products encompass the EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic tool for forecasting patient responses to checkpoint inhibitor immunotherapy; the EpiSwitch CST (Covid Severity Test), a sophisticated blood test designed to predict the severity of COVID-19 in adults; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome analysis and novel biomarker discovery. Established in 2007, Oxford BioDynamics Plc maintains its headquarters in Oxford, United Kingdom.